More Information Product Details Synonyms Product Type Properties Formula MW CAS Purity Chemicals Appearance Solubility Identity InChi Key Shipping and Handling Shipping Short Term Storage Long Term Storage Handling Advice Use/Stability Documents MSDS Product Specification Sheet Datasheet

4-((1-Butyl-3-phenylureido)methyl)-N-hydroxybenzamide

Chemical

C19H23N3O3

341.4

1403783-31-2

≥98% (HPLC)

Light pink solid.

Soluble in DMSO. Slightly soluble in methanol or ethanol (1mg/ml). Almost insoluble in water.

Determined by 1H-NMR.

JZWXMCPARMXZQV-UHFFFAOYSA-N

AMBIENT

+4°C

-20°C

Keep cool and dry.Protect from light.

Stable for at least 2 years after receipt when stored at -20°C.

Download PDF

Download PDF

• Cell permeable, potent and selective class IIb HDAC6 inhibitor (IC₅₀ =5.02nM). Displays high selectivity over all other HDACs (IC₅₀=3-10µM).
• Suppresses cell proliferation and promotes apoptosis in B16 cells (GI₅₀=14.3µM) and human lymphoma cells HuT-78. Dose-dependently induces hyperacetylation of α-tubulin in B16 murine melanoma cells without elevating histone H3 acetylation.
• Induces cell cycle arrest in G1.
• HDAC6 deacetylates tubulin, HSP90 and the core histones (H2A, H2B, H3, H4). Histone deacetylases act via the formation of large multiprotein complexes. HDAC6 plays an important role in microtubule-dependent cell motility, transcriptional regulation, degradation of misfolded proteins and cell cycle and is involved in autophagy, inflammation, cancer and neurodegeneration.

Product References

Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth: J.A. Bergman, et al.; J. Med. Chem. 55, 9891 (2012)

Development and therapeutic implications of selective histone deacetylase 6 inhibitors: J.H. Kalin & J.A Bergman; J. Med. Chem. 56, 6297 (2013)

Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation: K.V. Woan, et al.; Mol. Oncol. 9, 1447 (2015)

Trend of histone deacetylase inhibitors in cancer therapy: Isoform selectivity or multitargeted strategy: L. Zhang, et al.; Med. Res. Rev. 35, 63 (2015) (Review)

>>> 更多资讯详情请访问蚂蚁淘商城